Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T12:05:58.963Z.
Calculation as of: 2026-10-06T12:05:58.963Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cf0630fc9642b75147419b140bafddb7ccff0a2362c2d95f2dd7172ee2000ae5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$922.50M
EBITDA Yield
16.24%
TTM Avg
17.01%
3Y Avg
17.01%
5Y Avg
17.01%
Market Cap
$903.13M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$985.79M
EBITDA Yield
N/A
TTM Avg
50.22%
3Y Avg
50.22%
5Y Avg
50.22%
Market Cap
$867.60M
EBITDA Yield
N/A
TTM Avg
3.15%
3Y Avg
3.15%
5Y Avg
3.15%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $943.26M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 16.24% | 17.01% | 17.01% | 17.01% |
| Bioventus Inc. (BVS)vs › | $915.95M | 9.31% | 10.83% | 7.54% | 6.58% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | 50.22% | 50.22% | 50.22% |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | N/A | 3.15% | 3.15% | 3.15% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $844.28M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
